AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10496359 — intervention group
Group type: COMPARATOR
Intervention: MM
Number of subjects: 116
Study 10496359 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 116
Study 10496359 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF and MM
Number of subjects: 116
Study 9097707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus infection
Number of subjects: 55
Study 9097707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumocystis carinii infection
Number of subjects: 55
Study 9097707 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaposi's sarcoma
Number of subjects: 55
Study 9097707 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐Hodgkin's lymphoma
Number of subjects: 55
Study 1761875 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 7.5 mg
Number of subjects: 0
Study 1761875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7034164 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine, 25 mg at night + antacids 20 ml 1 and 3 h after meals
Number of subjects: 93
Study 7034164 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine, 400 mg at night + antacids 20 ml 1 and 3 h after meals
Number of subjects: 93
Study 7034164 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine, 1000 mg/day + antacids 20 ml 1 and 3 h after meals
Number of subjects: 93
Study 30877684 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 2013
Study 30877684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2013
Study 28209728 — intervention group
Group type: EXPERIMENTAL
Intervention: ALDHbr cells
Number of subjects: 82
Study 28209728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 25362864 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-1229 2.5 mg
Number of subjects: 158
Study 25362864 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-1229 5 mg
Number of subjects: 158
Study 25362864 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-1229 10 mg
Number of subjects: 158
Study 25362864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 25362864 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-1229 (all doses)
Number of subjects: 158
Study 25362864 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-1229
Number of subjects: 158
Study 25692840 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe
Number of subjects: 18144
Study 25692840 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin monotherapy
Number of subjects: 18144
Study 22465522 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention (LI)
Number of subjects: 75
Study 22465522 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 75
Study 19141621 — intervention group
Group type: EXPERIMENTAL
Intervention: Group affirmation (high identification condition)
Number of subjects: 0
Study 19141621 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-group derogation (high identification condition)
Number of subjects: 0
Study 19141621 — intervention group
Group type: COMPARATOR
Intervention: Self-affirmation (not specified if high or low identification)
Number of subjects: 0
Study 19141621 — intervention group
Group type: COMPARATOR
Intervention: Activism to change group behavior (low identification condition)
Number of subjects: 0
Study 17456124 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet with added information about NSAID interactions and ceiling effects
Number of subjects: 137
Study 17456124 — intervention group
Group type: COMPARATOR
Intervention: FDA pamphlet (control)
Number of subjects: 137
Study 15081625 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized scripts of traumatic situations
Number of subjects: 0
Study 15081625 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized scripts of abandonment situations
Number of subjects: 0
Study 15081625 — intervention group
Group type: COMPARATOR
Intervention: Standardized neutral scripts
Number of subjects: 0
Study 15081625 — intervention group
Group type: COMPARATOR
Intervention: Diastolic blood pressure and heart rate measures
Number of subjects: 0
Study 12204314 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg twice daily, n=53)
Number of subjects: 109
Study 12204314 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (75 mg twice daily, n=56)
Number of subjects: 109
Study 12204314 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 109
Study 12204314 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 109
Study 9718229 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (AChE inhibitor)
Number of subjects: 0
Study 9718229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7648385 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 42 micrograms twice daily
Number of subjects: 556
Study 7648385 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 180 micrograms four times daily
Number of subjects: 556
Study 7648385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plus as-needed albuterol)
Number of subjects: 556
Study 2559485 — intervention group
Group type: EXPERIMENTAL
Intervention: LMW‐heparinoid (n = 97)
Number of subjects: 196
Study 2559485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 99)
Number of subjects: 196
Study 692379 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline (4 mg)
Number of subjects: 14
Study 692379 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide (3 mg)
Number of subjects: 14
Study 692379 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg)
Number of subjects: 14
Study 692379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31929138 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education (GPR)
Number of subjects: 18
Study 31929138 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 18
Study 31187207 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota (LcS) ingestion
Number of subjects: 18
Study 31187207 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children without LcS exposure)
Number of subjects: 18
Study 29195999 — intervention group
Group type: EXPERIMENTAL
Intervention: Raisin consumption (90g/d)
Number of subjects: 36
Study 25520280 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for 30 minutes per day for 7 days at bilateral points ST36, LI4, TE6, ST37 and LR3
Number of subjects: 80
Study 25520280 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 80
Study 25520280 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electroacupuncture)
Number of subjects: 80
Study 23465062 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone followed after 48 hours by 400 μg oral misoprostol (Study One)
Number of subjects: 0
Study 23465062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone followed after 24 hours by 400 μg sublingual misoprostol (Study Two)
Number of subjects: 0
Study 21299448 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored doses of FEC chemotherapy
Number of subjects: 1535
Study 21299448 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of FEC chemotherapy
Number of subjects: 1535
Study 19922552 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive risperidone long-acting therapy (RLAT) plus treatment-as-usual (TAU) (n = 65)
Number of subjects: 124
Study 19922552 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive placebo injection plus treatment-as-usual (TAU) (n = 59)
Number of subjects: 124
Study 17121317 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoinositol (4 g daily) plus folic acid (400 microg daily)
Number of subjects: 176
Study 17121317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 15071291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 216
Study 15071291 — intervention group
Group type: COMPARATOR
Intervention: Control (no ciprofloxacin)
Number of subjects: 216
Study 11583074 — intervention group
Group type: EXPERIMENTAL
Intervention: Task Concentration Training (TCT)
Number of subjects: 31
Study 11583074 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo (EXP)
Number of subjects: 31
Study 11583074 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 31
Study 11583074 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 31
Study 9002079 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Enteral Nutrition (TEN)
Number of subjects: 30
Study 9002079 — intervention group
Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 30
Study 8240880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0
Study 8240880 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 8240880 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 3318442 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 1,200 mg daily
Number of subjects: 734
Study 3318442 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 750 mg daily
Number of subjects: 734
Study 3318442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study 29069400 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg LCB01-0371 once or twice daily for 21 days
Number of subjects: 40
Study 29069400 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg LCB01-0371 twice daily for 21 days
Number of subjects: 40
Study 29069400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27017611 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (60 mg/day)
Number of subjects: 100
Study 27017611 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (300 or 200 mg/day)
Number of subjects: 100
Study 24323402 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-based navigation
Number of subjects: 6
Study 24323402 — intervention group
Group type: COMPARATOR
Intervention: Individualized guides
Number of subjects: 6
Study 24349562 — intervention group
Group type: EXPERIMENTAL
Intervention: Force feedback during task performance
Number of subjects: 0
Study 24349562 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of scientific content
Number of subjects: 0
Study 19826944 — intervention group
Group type: EXPERIMENTAL
Intervention: tele-neurofeedback
Number of subjects: 17
Study 19826944 — intervention group
Group type: EXPERIMENTAL
Intervention: electromyography tele-biofeedback
Number of subjects: 17
Study 19826944 — intervention group
Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 17
Study 18621575 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic treatment with famciclovir (125 mg twice daily for 5 days)
Number of subjects: 384
Study 18621575 — intervention group
Group type: COMPARATOR
Intervention: Suppressive treatment with famciclovir (250 mg twice daily)
Number of subjects: 384
Study 16796221 — intervention group
Group type: EXPERIMENTAL
Intervention: Night work (6:30 PM to 6:30 AM)
Number of subjects: 17
Study 16796221 — intervention group
Group type: EXPERIMENTAL
Intervention: Day work (6:30 AM to 6:30 PM)
Number of subjects: 17
Study 12631176 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride-triclosan mouthrinse (AFT)
Number of subjects: 15
Study 12631176 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride (AmF)
Number of subjects: 15
Study 12631176 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan (TRI)
Number of subjects: 15
Study 12631176 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine solution (CHX)
Number of subjects: 15
Study 12631176 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (PLA)
Number of subjects: 15
Study 12370320 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) screening
Number of subjects: 0
Study 9524008 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (mean daily dose: 184 mg)
Number of subjects: 32
Study 9524008 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (IS-5-MN + Metoprolol)
Number of subjects: 32
Study 9524008 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) (mean daily dose: 33 mg)
Number of subjects: 32
Study 7974024 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy at 400 mg or 800 mg
Number of subjects: 22
Study 7974024 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy at 800 mg
Number of subjects: 22
Study 7974024 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy at 400 mg
Number of subjects: 22
Study 7974024 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy
Number of subjects: 22
Study 7974024 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (400 mg and 800 mg)
Number of subjects: 22
Study 2564243 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline, 110 mg
Number of subjects: 40
Study 2564243 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (Control)
Number of subjects: 40
Study 31531855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursery reared (NR)
Number of subjects: 39
Study 31531855 — intervention group
Group type: COMPARATOR
Intervention: Mother-peer-reared (MPR)
Number of subjects: 39
Study 31641325 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 85
Study 31641325 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 85
Study 30650270 — intervention group
Group type: EXPERIMENTAL
Intervention: Liujin Runzao Concentrated Decoction (LRCD), 30 mL twice per day for 4 weeks (two courses).
Number of subjects: 40
Study 30650270 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy: Radix Paeoniae alba total glycosides 600 mg, twice per day.
Number of subjects: 40
Study 30650270 — intervention group
Group type: EXPERIMENTAL
Intervention: Liujin Runzao Concentrated Decoction (LRCD) + Standard therapy.
Number of subjects: 40
Study 30650270 — intervention group
Group type: COMPARATOR
Intervention: Control group (Standard therapy only).
Number of subjects: 40
Study 30650270 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (LRCD + Standard therapy).
Number of subjects: 40
Study 25755266 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing sessions (4 sessions over 2 months)
Number of subjects: 31
Study 25755266 — intervention group
Group type: COMPARATOR
Intervention: Control group (no debriefing sessions)
Number of subjects: 31
Study 25755266 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing sessions
Number of subjects: 31
Study 23245454 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care
Number of subjects: 299
Study 23245454 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacute care
Number of subjects: 299
Study 23245454 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299
Study 22359978 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (3-month treatment with oral hormonal contraceptives: ethynil estradiol 35 microg plus cyproterone acetate 2 mg)
Number of subjects: 66
Study 22359978 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (3-month treatment with oral hormonal contraceptives: ethynil estradiol 35 microg plus cyproterone acetate 2 mg)
Number of subjects: 66
Study 18534405 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tourniquet release group
Number of subjects: 37
Study 18534405 — intervention group
Group type: COMPARATOR
Intervention: Late tourniquet release group
Number of subjects: 37
Study 16894412 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated single photon emission tomography (GSPET)
Number of subjects: 36
Study 16894412 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional echocardiography (ECHOC)
Number of subjects: 36
Study 15345808 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF drainage via low-flow ventriculoperitoneal (VP) shunt
Number of subjects: 0
Study 11329232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose‐intensive intravenous melphalan and autologous blood stem‐cell transplantation
Number of subjects: 65
Study 9499666 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy-based regimens for stage I peripheral BDHD
Number of subjects: 282
Study 9499666 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy or combined therapy for stage II BDHD
Number of subjects: 282
Study 9499666 — intervention group
Group type: COMPARATOR
Intervention: Overall survival (OS) for stage II BDHD vs stage II ADHD
Number of subjects: 282
Study 9499666 — intervention group
Group type: COMPARATOR
Intervention: Age-adjusted OS for BDHD vs ADHD
Number of subjects: 282
Study 9499666 — intervention group
Group type: COMPARATOR
Intervention: Prognostic factors for BDHD patients with intra-abdominal disease
Number of subjects: 282
Study 7836876 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cervical flexion/extension maneuvers
Number of subjects: 16
Study 7836876 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 16
Study 3597148 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intravesical misonidazole (MISO)
Number of subjects: 58
Study 3597148 — intervention group
Group type: COMPARATOR
Intervention: No misonidazole (Control)
Number of subjects: 58
Study 3597148 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study with MISO
Number of subjects: 58
Study 3597148 — intervention group
Group type: COMPARATOR
Intervention: Pilot study (historical controls)
Number of subjects: 58
Study 29016473 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load, higher-repetition training (LLHR)
Number of subjects: 15
Study 29016473 — intervention group
Group type: COMPARATOR
Intervention: High-load, lower-repetition training (HLLR)
Number of subjects: 15
Study 29016473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LLHR and HLLR
Number of subjects: 15
Study 31421816 — intervention group
Group type: EXPERIMENTAL
Intervention: P value threshold of .005
Number of subjects: 48
Study 31421816 — intervention group
Group type: COMPARATOR
Intervention: P value threshold of .05
Number of subjects: 48
Study 29216947 — intervention group
Group type: EXPERIMENTAL
Intervention: AACD‐CPR
Number of subjects: 69
Study 29216947 — intervention group
Group type: COMPARATOR
Intervention: STD‐CPR
Number of subjects: 69
Study 25733633 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (600 mg/d)
Number of subjects: 18
Study 25733633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 23944044 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhennaoning capsules
Number of subjects: 254
Study 23944044 — intervention group
Group type: COMPARATOR
Intervention: Yangxueqingnao granules
Number of subjects: 254
Study 21188594 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial Femoral Artery (SFA)
Number of subjects: 100
Study 21188594 — intervention group
Group type: COMPARATOR
Intervention: Common Femoral Artery (CFA)
Number of subjects: 100
Study 21188594 — intervention group
Group type: COMPARATOR
Intervention: Closure devices (subgroup analysis)
Number of subjects: 100
Study 19462303 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-Hydroxybutyric acid (GHB) administered intravenously, initially 30 mg/kg body weight (BW) followed by 15 mg/kg BW.
Number of subjects: 26
Study 19462303 — intervention group
Group type: COMPARATOR
Intervention: Clomethiazole (CLO) given orally to 12 patients in a dosage of 250 mg every 4 hours as a liquid.
Number of subjects: 26
Study 16758078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (8 sessions, 2 hours each, over one month)
Number of subjects: 38
Study 16758078 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 38
Study 15274672 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated pellets with pH‐dependent rapid release (EUDRAGIT FS 30D)
Number of subjects: 12
Study 15274672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pellets with pH‐ and time‐based release (inner layer EUDRAGIT RL/RS 30D; outer layer EUDRAGIT FS 30D)
Number of subjects: 12
Study 15274672 — intervention group
Group type: COMPARATOR
Intervention: Uncoated immediate release tablets
Number of subjects: 12
Study 11393182 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II of physiological labor
Number of subjects: 0
Study 11393182 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I in primiparae
Number of subjects: 0
Study 11393182 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I in multiparae
Number of subjects: 0
Study 9587285 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 ml of 2% lidocaine with 1:50,000
Number of subjects: 30
Study 9587285 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 ml of 2% lidocaine with 1:80,000
Number of subjects: 30
Study 9587285 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 ml of 2% lidocaine with 1:100,000
Number of subjects: 30
Study 9587285 — intervention group
Group type: COMPARATOR
Intervention: 1.8 ml of 2% lidocaine with 1:50,000
Number of subjects: 30
Study 9587285 — intervention group
Group type: COMPARATOR
Intervention: 1.8 ml of 2% lidocaine with 1:80,000
Number of subjects: 30
Study 9587285 — intervention group
Group type: COMPARATOR
Intervention: 1.8 ml of 2% lidocaine with 1:100,000
Number of subjects: 30
Study 8390795 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily antimony plus interferon-gamma (IFN-gamma) every other day (n = 10)
Number of subjects: 24
Study 8390795 — intervention group
Group type: COMPARATOR
Intervention: Daily pentavalent antimony (n = 14)
Number of subjects: 24
Study 3545618 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg
Number of subjects: 8
Study 3545618 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 8
Study 3545618 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg
Number of subjects: 8
Study 3545618 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 8
Study 3545618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8